Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease.

CREB-binding protein and p300 function as transcriptional coactivators in the regulation of gene expression through various signal-transduction pathways. Both are potent histone acetyl transferases. A certain level of CREB-binding protein is essential for normal development, since inactivation of one allele causes Rubinstein-Taybi syndrome (RSTS). There is a direct link between loss of acetyl transferase activity and RSTS, which indicates that the disorder is caused by aberrant chromatin regulation. We screened the entire CREB-binding protein gene (CBP) for mutations in patients with RSTS by using methods that find point mutations and larger rearrangements. In 92 patients, we were able to identify a total of 36 mutations in CBP. By using multiple ligation-dependent probe amplification, we found not only several deletions but also the first reported intragenic duplication in a patient with RSTS. We extended the search for mutations to the EP300 gene and showed that mutations in EP300 also cause this disorder. These are the first mutations identified in EP300 for a congenital disorder.

[1]  E. Seemanová,et al.  Molecular studies in 10 cases of Rubinstein-Taybi syndrome, including a mild variant showing a missense mutation in codon 1175 of CREBBP , 2002, Journal of medical genetics.

[2]  H. Masuya,et al.  Abnormal skeletal patterning in embryos lacking a single Cbp allele: a partial similarity with Rubinstein-Taybi syndrome. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Michael R. Green,et al.  Nuclear protein CBP is a coactivator for the transcription factor CREB , 1994, Nature.

[4]  H. Saal,et al.  Variation in microdeletions of the cyclic AMP-responsive element-binding protein gene at chromosome band 16p13.3 in the Rubinstein-Taybi syndrome. , 2000, American journal of medical genetics.

[5]  E. Kandel,et al.  Chromatin Acetylation, Memory, and LTP Are Impaired in CBP+/− Mice A Model for the Cognitive Deficit in Rubinstein-Taybi Syndrome and Its Amelioration , 2004, Neuron.

[6]  D. Zwijnenburg,et al.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. , 2002, Nucleic acids research.

[7]  Jonas Wittwer,et al.  Differential role of p300 and CBP acetyltransferase during myogenesis: p300 acts upstream of MyoD and Myf5 , 2003, The EMBO journal.

[8]  C. Cruaud,et al.  Molecular analysis of the CBP gene in 60 patients with Rubinstein-Taybi syndrome , 2002, Journal of medical genetics.

[9]  J. Opitz,et al.  Duplication of the MID1 first exon in a patient with Opitz G/BBB syndrome , 2003, Human Genetics.

[10]  H. Ugai,et al.  The coactivators p300 and CBP have different functions during the differentiation of F9 cells , 1999, Journal of Molecular Medicine.

[11]  M. Mayford,et al.  CBP Histone Acetyltransferase Activity Is a Critical Component of Memory Consolidation , 2004, Neuron.

[12]  Wei Gu,et al.  Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain , 1997, Cell.

[13]  C. Glass,et al.  Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome. , 2001, Human molecular genetics.

[14]  R. Goodman,et al.  Adenoviral ElA-associated protein p300 as a functional homologue of the transcriptional co-activator CBP , 1995, Nature.

[15]  S. Antonarakis,et al.  Nomenclature for the description of human sequence variations , 2001, Human Genetics.

[16]  R. Goodman,et al.  CBP/p300 in cell growth, transformation, and development. , 2000, Genes & development.

[17]  R. W. Miller,et al.  Tumors in Rubinstein-Taybi syndrome. , 1995, American journal of medical genetics.

[18]  C. Hui,et al.  Developmentally regulated expression of the transcriptional cofactors/histone acetyltransferases CBP and p300 during mouse embryogenesis. , 1999, The International journal of developmental biology.

[19]  J. Schouten,et al.  Two‐color multiplex ligation‐dependent probe amplification: Detecting genomic rearrangements in hereditary multiple exostoses , 2004, Human mutation.

[20]  David Newsome,et al.  Gene Dosage–Dependent Embryonic Development and Proliferation Defects in Mice Lacking the Transcriptional Integrator p300 , 1998, Cell.

[21]  L. Deaven,et al.  Construction of a 1.2-Mb contig surrounding, and molecular analysis of, the human CREB-binding protein (CBP/CREBBP) gene on chromosome 16p13.3. , 1997, Genomics.

[22]  D. Livingston,et al.  Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation , 1998, Nature.

[23]  R. Hennekam,et al.  Loss of CBP acetyltransferase activity by PHD finger mutations in Rubinstein-Taybi syndrome. , 2003, Human molecular genetics.

[24]  Andrew J. Bannister,et al.  The CBP co-activator is a histone acetyltransferase , 1996, Nature.

[25]  S. Balcı,et al.  FISH studies in 45 patients with Rubinstein-Taybi syndrome: deletions associated with polysplenia, hypoplastic left heart and death in infancy , 1999, European Journal of Human Genetics.

[26]  Raoul C. M. Hennekam,et al.  Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP , 1995, Nature.

[27]  R. Hennekam,et al.  Diagnostic analysis of the Rubinstein-Taybi syndrome: five cosmids should be used for microdeletion detection and low number of protein truncating mutations , 2000, Journal of medical genetics.

[28]  E. Kalkhoven,et al.  CBP and p300: HATs for different occasions. , 2004, Biochemical pharmacology.